At the Glial meeting in Portugal, we had the fantastic opportunity of interviewing Ana Mendanha Falcão about her research on oligodendrocytes and her experiences on acquiring viable glial cells from adult brain tissues.
Browsing: multiple sclerosis
This week in industry includes trials on elenbecestat to be discontinued, ofatumumab demonstrating superiority to Aubagio and the Toca 5 trial results failing to meet primary endpoint.
Physician and patient treatment decision-making in relapsing–remitting multiple sclerosis in Europe and the USA
In this interview from the Video Journal of Biomedicine, Hannah Brown (Ipsos Healthcare, London, UK) discusses physician and patient treatment decision-making for relapsing–remitting multiple sclerosis.
What have been the biggest headlines in industry this week? Take a look at our highlights including positive news about two monoclonal antibodies for relapsing multiple sclerosis and neuromyelitis optica spectrum disorder.
Chronic active lesions (‘smoldering’ spots) may be a hallmark for progressive forms of multiple sclerosis, a recently published study suggests.
Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
MRI scans of individuals living with multiple sclerosis could predict how the disease will progress in the following years. This information could potentially be useful when considering treatment options.
A 65-year follow-up study of approximately 7000 multiple sclerosis patients has uncovered that overall, patients are 14% more likely to develop cancer compared to individuals without the disease.
A team of researchers have utilized radiocarbon dating to determine that there is little regeneration of oligodendrocytes in the brains of people living with multiple sclerosis. However, the oligodendrocytes that survive the autoimmune attack can replenish lost myelin.
In this research article from Biomarkers in Medicine, researchers determine if serum levels of tau and BDNF can be used as severity biomarkers in multiple sclerosis.